No Data
Express News | Chengda Pharmaceuticals Says Key Shareholder to Unload up to 3.23% Stake in Three Months
Chengda Pharmaceutical (301201.SZ): Qianhai Shengtai plans to reduce its shareholding by no more than 3.23%.
On May 7, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) announced that shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership), which holds 15,901,840 shares of the company (10.50% of the total share capital calculated after excluding shares in the repurchase account), plans to reduce its shareholding in the company by no more than 4,894,943 shares (3.23% of the total share capital calculated after excluding shares in the repurchase account) through block trades within three months after 15 trading days from the date of announcement (from May 30, 2025, to August 29, 2025).
Chengda Pharmaceutical (301201.SZ) mainly serves B-end clients and has not yet engaged in cross-border e-commerce business.
On April 30, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated on the interactive platform that the company's main customers are B-end clients, and it currently does not involve cross-border e-commerce. In 2024, the company's R&D expenses are 93.7096 million yuan, of which 54.752 million yuan is allocated for the stem cell business (including projects for cell therapy on heart failure after acute myocardial infarction and for treating sequelae during the subacute phase after cerebral infarction).
Chengda Pharmaceutical: 2024 Annual Report
Chengda Pharmaceutical: 2024 Annual Report Summary
Chengda Pharmaceutical: Report for the first quarter of 2025